Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance

As oral JAK inhibitors move through late-stage trials for vitiligo, the choice between topical and systemic therapy comes down to 2 questions, Iltefat Hamzavi, MD, told Dermatology Times at the 2026 Fall Clinical Dermatology Conference in Las Vegas: how much of the body is involved, and whether the disease is stable.

Hamzavi, a dermatologist at Henry Ford Health and Hamzavi Dermatology, noted that the field is “a little further along in the JAK topical area and we’re really getting into the JAK oral phase.”

When To Move From Topical to Oral JAK Inhibitors

Topical ruxolitinib is best suited to localized disease without markers of instability, Hamzavi said. On examination, he looks for 3 physical findings, including trichrome lesions and confetti-like depigmentation, that signal a patient may develop unstable vitiligo, which he defined as an increase in affected surface area.

He considers disease covering less than 10% of body surface area to be localized. “Once you’re going beyond 10%, you’re putting a lot of cream on somebody, you’re gonna have a risk of side effects, so it’s better to go to oral,” he said. Patients with instability or progressive disease are also candidates for systemic therapy.

Why Topicals Remain the Preferred Agent for Limited Disease

For limited, stable disease, topical JAK inhibitors have become the preferred agent largely because of their safety record, Hamzavi said. Before ruxolitinib cream, clinicians used topical calcineurin inhibitors and steroids off-label with little long-term data, a significant gap given that vitiligo requires much longer treatment than eczema.

Clinicians now also have data on combining the cream with phototherapy, which he described as “really needed to get the pigmentation going.”

Oral JAK Inhibitor Safety: When It Is Contraindicated

Oral agents carry theoretical cardiovascular and infection risks, but in the phase 3 trials, “we’re not seeing too many internal side effects, but there are a few elements that you watch out for,” Hamzavi told Dermatology Times. He avoids oral JAK inhibitors in patients with active cardiovascular risk, high body mass index, smoking, a strong family history, or very high cholesterol, though most patients, particularly younger ones, do not have those risk factors.

For those patients, oral JAK inhibitors offer an alternative to the previous options for rapidly progressive vitiligo: oral steroids, which cause many adverse effects beyond 3 to 4 weeks, or methotrexate, which can damage the liver. “You can really stabilize vitiligo with these JAK inhibitors a lot better than you could before,” he said.

Why Stabilizing Vitiligo Early Matters

Halting progression matters because melanocytes, which derive from the neural crest, turn over only once or twice a year, so repigmenting the skin can take a year, Hamzavi explained. In the meantime, the resulting disfigurement carries a tremendous psychosocial impact.

“We know how to mitigate and reduce the side effects, but we can also keep people from being permanently disfigured by stopping the vitiligo from progressing,” he said.